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Abstract
OBJECTIVE: To review the efficacy of Tianshu cap-
sule in the treatment of migraine.
METHODS: Retrieving papers from Pubmed, co-
chrane central register of controlled trials (CEN-
TRAL), Weipu database (VIP) , China biology medi-
cine (CBM), China national knowledge infrastruc-
ture (CNKI), and Wanfang Data. Two reviewers re-
trieved and extracted the information indepen-
dently. Retrieval time scale is up to August 2012.
Software Review Manager 5.1 was used for analysis.
RESULTS: A total of 10 studies including 937 mi-
graine patients. The merged data shows Tianshu
capsule had a higher effective rate in treating mi-
graine, and there is no significant heterogeneity be-
tween Tianshu capsule group and control group
(χ2=6.33, df=9, P=0.71, I2=0% ), OR=4.18 [95% CI
(2.93,5.95)]. Tianshu capsule alone compared to
conventional therapy also showed advantages, and
there was low heterogeneity (χ2=4.53, df=3, P=0.21,
I2 = 34%), OR=3.95 [95% CI (2.32, 6.72)]. Meta-analy-
sis results show that clinical efficacy of Tianshu cap-
sule was better than that of the control group in
the treatment of migraine and there was a signifi-
cant difference (P<0.000 01).
CONCLUSION: Tianshu capsule had better efficacy
in the treatment of migraine with fewer adverse ef-
fects.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Migraine is a chronic neurological disorder. Its symp-
toms include one side or bilateral headaches, often ac-
companied by nausea, vomiting or visual disturbances.1
Studies show that about 6.5% of men and 18.2% of
women suffer from migraine.2 Most patients are wom-
en at the age of 20-40.3 Flunarizine is the only effective
calcium antagonist medicine in preventing migraine
proved by evidence-based research.4 Traditional Chi-
nese Medicine (TCM) has a long history in the treat-
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ment of migraine. Tianshu capsule (Kanion pharma-
ceutical, Lianyungang, Jiangsu, China) is an effective
Chinese patent medicine for the disease, which can, in
terms of TCM theory, soothe liver, activate blood, and
relieve pain. It can be traced back to Da Xiong Wan, a
classic prescription in Sheng Ji Zonglu in the Song Dy-
nasty (A.D. 1117).5 This study performed a meta-anal-
ysis of the randomized controlled trials (RCTs) con-
duced to evaluate the efficacy of Tianshu capsule on
migraine.
MATERIALS ANDMETHODS
Literature retrieval
Two reviewers searched the RCTs conducted for Tians-
hu capsule in treating migraine both in English and
Chinese from the database of Pubmed (1966-2012.8),
cochrane central register of controlled Trials (CEN-
TRAL) (2012, Issue3), Weipu database (VIP, 1989-
2012.8), China biology medicine (CBM, 1979-
2012.8), China national knowledge infrastructure
(CNKI, 1994-2012.8), and Wanfang Data(1980-
2012.8). The search term were Tianshu capsule, and
migraine.
Inclusion criteria
1) Definite diagnosis: the final diagnosis of migraine,
in terms of the diagnostic criteria- "the International
Classification of Headache Disorders";6 2) RCTs; 3)
Homogeneity between groups was required, and the re-
search was comparable; 4) Evaluation of effectiveness
of the medication should be the generally accepted at
home and abroad; 5) The experiment group was treat-
ed with Tianshu capsule, the control group's interven-
tion was conventional therapy.
Exclusion criteria
1) Any non-RTCs studies; 2) Diagnosis complicated
with pregnancy, stroke, endocrine diseases, or severe
diseases of heart, liver, kidney, and hematopoietic
system; 3) Data could not be utilized in the study.
Data extraction and assessment of methodological
quality
Two reviewers independently perused the papers re-
trieved, screened out the unaccepted ones according to
the inclusion and exclusion criteria and had their out-
comes cross-checked. If there was any difference, they
would make a decision to keep or discard by delibera-
tion. The risk of bias of those included trials were as-
sessed strictly according to the Cochrane Collaboration
the system evaluators manual version 5.17 Assessment
included random sequence generation, allocation con-
cealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data,
selective reporting, and other bias. Each entry corre-
sponded respectively to yes, no, or unclear.
Data analysis
Cochrane Collaboration the Review Manager 5.1 was
used for data analysis. For count data odds ratio (OR)
was be used with confidence interval (CI) of 95%, and
for heterogeneity between studies Chi-square test analy-
sis used. If P>0.1, I2<50% , it signified no significant
heterogeneity. The fixed effects model was chosen if
there was no significant heterogeneity. If there was het-
erogeneity, subgroup analysis could be performed first.
However, the random effects model analysis would be
used if there was still heterogeneity. Potential publica-
tion bias would be checked with funnel plot.
Search results
We collected a total of 39 articles initially, Wanfang
(n=31), CBM (n=43), VIP (n=59), CNKI (n=57),
Pubmed (n=0), CENTRAL (n=0). After 25 duplicates
were removed, 14 records remained for study; further,
four of them were excluded due to incomplete data; fi-
nally 10 RCTs8-17 were available. They were involved in
937 patients. The basic characteristics are shown in Fig-
ure 1, Figure 2 and Table 1, Table 2.
Effective rate meta-analysis
The clinical efficacy of Tianshu capsule was compared
with that of conventional therapy by 10 trials.8-17 No
significant heterogeneity between studies (χ2=6.33, df=
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting(reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
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Figure 1 Risk of bias of included trials
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9, P=0.71, I2=0% ), OR=4.18 [95% CI (2.93,5.95)].
Fixed effects model analysis was used. The result
showed that Tianshu capsule combined with other
drugs had a higher effective rate than that in the con-
trol group (P<0.000 01, Figure 3). The funnel-shape
was a little asymmetrical, indicating that there might
be publication bias in those studies. The reason might
be that all studies conducted in China and some re-
searchers were unwilling to publish negative results.
Subgroup analyses
Evaluation of a single drug and combination of the
drug with Tianshu capsule in the treatment of mi-
graine: 4 studies12, 14-16 took only Tianshu capsule as ex-
perimental group, 6 studies 8-11,13,17 used both Tianshu
capsule and other drugs as experimental group, the con-
trol groups were given conventional therapy. There was
no significant heterogeneity (χ2=4.53, df=3, P=0.21, I2=
34%), the fixed effects model analysis was used. The re-
Figure 2 Conclusion of risk of bias
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting(reporting bias)
Other bias
ChaiJJ2009 8
JiXL2006 9
MaXD2011 10
MaXD2012 11
MengDJ2004 12
MengL2008 13
QiaoSL2008 14
QinJW
2009 15
SunXJ2009 16
ZhaoR2008 17
Reference
Chai JJ
20098
Ji XL
20069
Ma XD
201110
Ma XD
201211
Meng DJ
200412
Meng L
200813
Qiao SL
200814
Qin JW
200915
Sun XJ
200916
Zhao R
200817
No. of
patients
(T/C)
55/40
40/40
50/50
40/40
59/59
40/46
51/45
48/40
58/32
50/50
Age(T/C)
l6-52/
Unclear
16-54/
15-52
14-53
15-55
35.2±9.87
21-55
18-57
/17-49
18-57/
17-49
47±16/
35±10
16-54/
15-52
M/F
(T/C)
10/45 vs
Unclear
16/24 vs
15/25
45/55
35/45
48/70
40/50
18/33 vs
16/29
26/22 vs
16/24
20/38 vs
6/16
21/29 vs
24/26
Disease course
(T/C)
>2 Months
>3 Months/
>3 Months
>3 Months
>3 Months
Unclear
>3 Months
(4±2) Years/
(5±2) Years
Unclear
(7±7) Years
/(7±8) Years
>3 Months/
>3 Months
Intervention
(T/C)
Tianshu capsule+Flunarizine
Hydrochloride capsule /Flunarizine
Hydrochloride capsule
Tianshu capsule+Flunarizine
Hydrochloride capsule /Flunarizine
Hydrochloride capsule
Tianshu capsule+Yangxue
QingnaoKeli/Flunarizine
Hydrochloride capsule
Tianshu capsule+Flunarizine
Hydrochloride capsule /Flunarizine
Hydrochloride capsule
Tianshu capsule/Doufuguogan tablet
Tianshu capsule+Stellate ganglion
block/Stellate ganglion block
Tianshu capsule/Flunarizine
Hydrochloride capsule
Tianshu capsule/Flunarizine
Hydrochloride capsule
Tianshu capsule/Compound
Paracetamol tablet
Tianshu capsule+acupuncture/
Flunarizine
Hydrochloride capsule
Dose usage
(T/C )
4 capsules tid po+
1capsule qd/1capsules
qd
4 capsules tid po
+unclear/ unclear
4 capsules tid po
+4g tid/1capsule qd
4 capsules tid po+
1capsule qd/1capsule
qd
4 capsules tid
/2 pills qd
4 capsules tid po
4 capsules tid
/2 capsules qd
4 capsules tid
/2 capsules qd
4 capsules tid po
/1pill qd
4 capsules tid po
+ acupuncture qd
/5 mg qd
Table1 Characteristics of studies included in the meta-analysis 1
Notes: T: test group, C: control group; Some studies10-11 only provided a total data about age.
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sults showed that the groups of Tianshu capsule plus
other drug had higher effective rate than that in their
control groups, and the difference was statistically sig-
nificant (P<0.000 01, Figure 4).
Sensitivity analysis
Compared to their control groups, the ORs for the
group of Tianshu capsule combined with other drugs
and the group used Tianshu capsule only were 4.18
[95% CI (2.93,5.95)] and OR=3.95 [95% CI (2.32,
6.72)] respectively. There was no obvious change of
OR values under different interventions, which indi-
cates the good stability of this result.
Adverse reactions
Seven studies8,10-11,14-17 mentioned adverse reactions. Ad-
verse reactions were mainly abdominal discomfort. No
liver and kidney injuries were reported. The analysis
showed no significant difference between the experi-
ment group and the control group (P=0.07).
DISCUSSION
The meta-analysis was proved to be one of the reliable
methods for the evaluation of some drugs' efficacy and
safety in the treatment regimen.18 Migraine is called
"Pian Tou Feng" in Traditional Chinese Medicine
(TCM). It considers that the cause of the condition is
Qi stagnation due to liver cold. Cold pathogen invades
the Liver Meridian, and then goes upward to the top
through the liver Meridian and cause headache. Other
pathogenic factors like wind, fire, phlegm, blood stasis
are also playing an important role in migraine onset.
The disease is involved in liver and gallbladder viscera
in terms of TCM theory. The pathogenesis is the distur-
bance of Qi-movement, and the pathological feature is
manifested as Qi stagnation and blood stasis.19 Tianshu
capsule was prepared with Chinese herbal medicinal
compounds had muti-target effect.20 The formulas of
tianshu capsule is composed of Tianma (Rhizom Gastro-
diae), Chuanxiong (Rhizoma Chuanxiong). Rhizom
Gastrodiae functions as calming the liver and suppress-
ing Yang, dispelling wind and regulating the meridians,
and it is the key herb in treating headache and dizzy.
Its components are gastrodin, vanillyl alcohol, vanil-
lin.21 Rhizoma Chuanxiong's function is promoting the
flow of Qi and blood circulation, dispelling wind and
relieving pain. It is an herb used for blood disorder
Reference
Chai JJ 20098
Ji XL 20069
Ma XD 201110
Ma XD 201211
Meng DJ 200412
Meng L 200813
Qiao SL 200814
Qin JW 200915
Sun XJ 200916
Zhao R 200817
Trial period
(day)
30
28
30
28
30
30
90
90
7
28
Outcome measures
Symptom improvement, headache severity
Score, headache duration, adverse reactions
Symptom improvement,
Electroencephalogram
Symptom improvement, headache severity
Score, headache duration, adverse reactions
Symptom improvement, headaches
Everity score, headache duration, adverse reactions
Symptom improvement, adverse reactions
Symptom improvement, adverse reactions
Symptom improvement, adverse reactions
Headache severity score, headache duration,
Adverse reactions
Symptom improvement, headache severity score,
Headache duration, adverse reactions
Symptom improvement, adverse reactions
Follow up
6 Months
1 Year
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Effective rate (%)(T/C)
96.36
87.50
88
87.5
81.36
86.36
90.20
89.59
96.55
94
82.5
67.50
64
65
67.80
65.22
64.44
65
68.75
64
Table 2 Characteristics of studies included in the meta-analysis 2
Note:s T: test group; C: control group.
Figure 3 Meta-analysis of Tianshu capsule combined with other drugs
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Figure 4 Meta-analysis of subgroups
complicated by Qi disorder. It contains volatile oil, tet-
ramethylpyrazine, perlolyrine.22 With fewer adverse re-
actions, Tianshu capsule contains this two herbs and
has definite effect on migraine.
Limitations of this systematic review and direction
for future clinical research
This review included a total of 10 trials, but they
lacked large-scale, multi-centered RCTs and few of
them adopted blinding method. So rigorously designed
RCTs are needed to further provide more accurate data
so as to verify the efficacy of Tianshu capsule on mi-
graine.
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